Foreign businesses worry that tough quarantines and restrictions could persist into next year as Beijing struggles with variants and questions about its vaccines.
An inoculation push, plagued with limited supplies and red tape, makes doses available to those who can pay for them. In a country with a struggling economy, most can’t.
By playing off its big neighbors, Russia and China, Mongolia has emerged as a positive outlier among developing nations on the hunt for shots.
Seychelles has seen a surge in coronavirus cases despite much of its population being inoculated with China’s Sinopharm vaccine.
The popular cleric Moktada al-Sadr got a coronavirus vaccine, persuading many of his followers to do the same. Yet millions of Iraqis remain unconvinced.
The World Health Organization has approved a Chinese vaccine for emergency use. The announcement comes at a time when officials in the country are warning of a domestic shortage.
A new rule for foreigners applying in Hong Kong for visas gives preference to those who choose shots produced in China.
Hungary has agreed to pay $36 per dose of the Sinopharm vaccine, according to contracts that were leaked by a Hungarian official.
The coronavirus threat is global. So is the remedy.
They, too, work, and they can help fill shortages everywhere.
Delays, inconsistent data, spotty disclosures and the country’s attacks on Western rivals have marred its ambitious effort to portray itself as a leader in global health.